148 related articles for article (PubMed ID: 24870789)
41. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.
Kerekes D; Visscher DW; Hoskin TL; Radisky DC; Brahmbhatt RD; Pena A; Frost MH; Arshad M; Stallings-Mann M; Winham SJ; Murphy L; Denison L; Carter JM; Knutson KL; Degnim AC
Breast Cancer Res Treat; 2018 Feb; 167(3):649-658. PubMed ID: 29090365
[TBL] [Abstract][Full Text] [Related]
42. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
43. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Factors for Breast Cancer: an Immunomorphological Update.
Roncati L; Barbolini G; Piacentini F; Piscioli F; Pusiol T; Maiorana A
Pathol Oncol Res; 2016 Jul; 22(3):449-52. PubMed ID: 26589512
[TBL] [Abstract][Full Text] [Related]
45. Hot Spot and Whole-Tumor Enumeration of CD8
McIntire PJ; Irshaid L; Liu Y; Chen Z; Menken F; Nowak E; Shin SJ; Ginter PS
Clin Breast Cancer; 2018 Dec; 18(6):451-458.e1. PubMed ID: 29866579
[TBL] [Abstract][Full Text] [Related]
46. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
[TBL] [Abstract][Full Text] [Related]
47. CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.
Triki H; Charfi S; Bouzidi L; Ben Kridis W; Daoud J; Chaabane K; Sellami-Boudawara T; Rebai A; Cherif B
Life Sci; 2019 Aug; 231():116543. PubMed ID: 31176775
[TBL] [Abstract][Full Text] [Related]
48. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.
Tramm T; Di Caterino T; Jylling AB; Lelkaitis G; Lænkholm AV; Ragó P; Tabor TP; Talman MM; Vouza E;
Acta Oncol; 2018 Jan; 57(1):90-94. PubMed ID: 29168428
[TBL] [Abstract][Full Text] [Related]
49. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.
Pupa SM; Bufalino R; Invernizzi AM; Andreola S; Rilke F; Lombardi L; Colnaghi MI; Ménard S
J Clin Oncol; 1996 Jan; 14(1):85-94. PubMed ID: 8558226
[TBL] [Abstract][Full Text] [Related]
50. Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study.
Almangush A; Ruuskanen M; Hagström J; Hirvikoski P; Tommola S; Kosma VM; Nieminen P; Mäkitie A; Leivo I
Hum Pathol; 2018 Nov; 81():211-219. PubMed ID: 30030117
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis.
Zhang S; Liu W; Hu B; Wang P; Lv X; Chen S; Shao Z
Front Immunol; 2020; 11():1242. PubMed ID: 32714321
[No Abstract] [Full Text] [Related]
53. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
Shou J; Zhang Z; Lai Y; Chen Z; Huang J
BMC Cancer; 2016 Aug; 16(1):687. PubMed ID: 27566250
[TBL] [Abstract][Full Text] [Related]
54. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
55. CD103 and Intratumoral Immune Response in Breast Cancer.
Wang ZQ; Milne K; Derocher H; Webb JR; Nelson BH; Watson PH
Clin Cancer Res; 2016 Dec; 22(24):6290-6297. PubMed ID: 27267849
[TBL] [Abstract][Full Text] [Related]
56. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.
De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Rottey S; Ferdinande L
Pathology; 2017 Jun; 49(4):397-404. PubMed ID: 28427753
[TBL] [Abstract][Full Text] [Related]
57. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
Yakirevich E; Izhak OB; Rennert G; Kovacs ZG; Resnick MB
Mod Pathol; 1999 Nov; 12(11):1050-6. PubMed ID: 10574602
[TBL] [Abstract][Full Text] [Related]
58. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
[TBL] [Abstract][Full Text] [Related]
59. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
60. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
Carrega P; Morandi B; Costa R; Frumento G; Forte G; Altavilla G; Ratto GB; Mingari MC; Moretta L; Ferlazzo G
Cancer; 2008 Feb; 112(4):863-75. PubMed ID: 18203207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
